{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2008"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2061238"],"location":["Greece"],"study_start_month":["10"],"keyword":["Second line","Irinotecan","Oxaliplatin","Leucovorin","Cetuximab","Metastatic colorectal cancer","Fluorouracil","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc","description":"The aim of this study is to evaluate the efficacy of the effective drugs in a alternating chemotherapy schedules in pretreated patients with mCRC, who have received all effective drugs.","dates":{"creation":"2008-10-15"},"accession":"2061238","cross_references":{"ClinicalTrials___gov":["NCT00755118"]}}